Evaxion A/S

Greetings and welcome to the Evaccion Biotech fourth quarter and full year 2021 earnings call. At this time, all participants are on the listen-only mode. A question and answer session will follow the formal presentation. If you would like to ask a question, please press star 1 on your telephone keypad. If anyone should require operator assistance, please press star 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Corey Davis. Thank you, sir. Please go ahead.

Thanks, Donna. And hello, everyone. Thanks for joining us. Let me quickly remind you that today's discussion contains certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties, they are not guarantees of future performance and actual results may differ materially. from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company's prospectus filed on November 5th, 2021, and the company's current and future reports filed with or submitted to the Securities and Exchange Commission. At this time, I'd like to turn the call over to Lars Wigner, the company's president and CEO. Go ahead, Lars.

Thank you, Corey. Good morning, everyone. Thank you for joining us for this Evaction Biotech Q4 earnings call. I'm Lars Wikner, the chief executive officer of Evaction. With me today is Evaction's co-founder and chief business officer, Nils Møller, who is currently the interim chief financial officer. We'll give you a short presentation on our business and results, and then open the call up for any questions you may have. Let me begin. by saying Evaction continues to demonstrate exciting clinical momentum in the fourth quarter of 2021 towards our goal of becoming a world leader in AI-driven immune therapies. As many of you know, Evaction specializes in decoding the human immune system and using the data to rapidly discover and develop potentially effective drug candidates to improve the lives of patients with cancer and infectious disease. We believe that our AI models allow us to identify unique drug targets, which may translate into a higher likelihood of clinical success. In October 2021, we announced a clinical trial collaboration and supply agreement with Merck, one of the world's leading immune oncology companies, to evaluate the combinations of Evaction's cancer immune therapy, EVX01, in combination with Merck's Kethrutin, in a Phase IIb clinical trial in patients with metastatic melanoma. In January 2022, we received regulatory clearance to initiate this Phase IIb trial of EVX01 with Cthulhu. We plan to have the first patient's first visit for EVX01 in the first half of 2022. Also in January 22, we completed recruitment for our Phase I-IIa clinical trial for EVXO2, advancing into a dedicated Phase IIb clinical adjuvant trial in patients with resectable melanoma. We plan to file for regulatory clearance for EVXO1-O3 in patients with resectable melanoma by the first half of 2022, and have first patient first visit in by second half of 2022. The EVX01, 02, and 03 products all come from our pioneer AI platform, which generates patient-specific cancer immune therapies. In other development areas outside cancer, we remain on track on the lead candidate on our EDEN platform, which generates vaccines against bacterial diseases. This program, EVX, B1 is a vaccine for the prevention of staph aureus in skin and soft tissue infections. We also plan to select our second bacteria product candidate in the first half of 2022. We plan to select the first viral candidate from our Raven platform in the second half of 2022. Outside of the clinic. We closed our follow-on public offering in November 2021, raising net proceeds of 24.9 million U.S. dollars. Evaction also received the 2021 Enabling Technology Leadership Award in the Artificial Intelligence Enabling Drug Discovery Industry by the leading global research and consulting firm Frost & Sullivan. We are honored to receive the award, and I'm very proud of the hard work and commitment of the whole Evaction team in advancing our vision for better global health. Evaction also gave a presentation at the Immuno UK conference, which was held in London. One of our senior scientists, Emma-Christine Jappe, introduced Evaction's AI immunological core technology, and detailed how the company is using AI to decode the human immune system. She focused on Pioneer and demonstrated how Evaction is continuously working to improve the platform through immunological data generation and the development of optimized AI models. This concludes our business and operational updates for Q4 2021. I will now turn the call over to Nils for news on our follow-on public offering and the 2021 financial review.